A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Inclusion Criteria

• •Diagnosis of Hodgkin's disease \[HD\] (excluding HIV-associated HD)
• •Patients must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained
• •Patients must have failed or relapsed following second line (i.e., salvage) chemotherapy or relapsed or failed following autologous stem cell transplant
• •ECOG Performance Status of 0-2
• •Patients must have bi-measurable disease
• •At least 4 weeks since the last chemotherapy or radiation therapy with clinical evidence of recovery from any toxicity associated with such treatment
• •Life expectancy 12 weeks or greater
• •Screening laboratory values must be met
• •Patients on corticosteroids must be tapered off the medication 2 weeks prior to study drug administration and remain off corticosteroids until study completion.